PT - JOURNAL ARTICLE AU - Maeva Zysman AU - Pierre Regis Burgel AU - Jean Louis Paillasseur AU - Pascal Chanez AU - Denis Caillaud AU - Roger Escamilla AU - Isabelle Court Fortune AU - Pascal Nesme Meyer AU - Graziella Brinchault Rabin AU - Gaetan Deslee AU - Thierry Perez AU - Christophe Pinet AU - Nicolas Roche TI - Relationship between blood eosinophil count (Eos), clinical characteristics and mortality of patients with COPD AID - 10.1183/13993003.congress-2016.PA4614 DP - 2016 Sep 01 TA - European Respiratory Journal PG - PA4614 VI - 48 IP - suppl 60 4099 - http://erj.ersjournals.com/content/48/suppl_60/PA4614.short 4100 - http://erj.ersjournals.com/content/48/suppl_60/PA4614.full SO - Eur Respir J2016 Sep 01; 48 AB - Background: Several studies suggest that, in patients with COPD, Eos is associated with (i) exacerbation frequency and (ii) the effect of inhaled corticosteroid for exacerbation prevention.Aim: To determine whether Eos defines patients' groups exhibiting attributes of COPD clinical phenotypes, we compared the clinical features and mortality rate between COPD patients with ≥2% (Eos+) and <2% (Eos-) blood eosinophils in the Initiatives BPCO French cohort.Methods: The following data were collected at inclusion: medical and smoking history, occupational exposures, dyspnea, cough and sputum production, exacerbations in the previous year, history of allergy and asthma, nasal symptoms, BMI, SGRQ score, post-bronchodilator spirometry and plethysmography, comorbidities, CRP and medications. Three-year survival was available for all patients. BOD and ADO scores were calculated.Results: Eos was available in 458 patients (mean age: 62 years, 72% male, mean FEV1: 51%), including 235 Eos+ patients (49%). No difference between Eos+ and Eos- groups was observed in univariate analyses except for diabetes (17% in Eos-, 8% in Eos+, p=0.02) and SGRQ score (mean, 48 units in Eos -, 40 units in Eos+, p=0.007). In particular, there was no difference in term of exacerbations rate (mean, 1.6/patient/year) or history of asthma (15% of the population). Three-year mortality rate was 17% in Eos- vs 13% in Eos+ (NS).Conclusion: Apart from differences in health-related quality of life and frequency of diabetes (which warrant further investigation), Eos+ COPD patients exhibit no specific clinical characteristic, especially regarding symptoms, lung function, exacerbations and prognosis.